Ποια είναι η τιμή για MetaVia Inc. (MTVA)

Η τιμή για MetaVia Inc. (MTVA) είναι $1.51

Ποια είναι η κεφαλαιοποίηση αγοράς για MetaVia Inc. (MTVA)

Η κεφαλαιοποίηση αγοράς για MetaVia Inc. (MTVA) είναι $3.32M

MetaVia Inc. (MTVA) Διαίρεση Μετοχών

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

Έτος	Διάσπαση	Πολλαπλασιαστής	Αθροιστικός Πολλαπλασιαστής
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

Διάσπαση

Πολλαπλασιαστής

Αθροιστικός Πολλαπλασιαστής

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	Αριθμός διασπάσεων μετοχών	Αθροιστικός Πολλαπλασιαστής	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Εταιρεία

Αριθμός διασπάσεων μετοχών

Αθροιστικός Πολλαπλασιαστής

Χώρα